These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17987400)

  • 21. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
    Callens S; Bottieau E; Michielsen P; Colebunders R
    AIDS; 2004 Jan; 18(1):131. PubMed ID: 15090841
    [No Abstract]   [Full Text] [Related]  

  • 23. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection.
    Adişen E; Dizbay M; Hizel K; Ilter N
    Indian J Dermatol Venereol Leprol; 2008; 74(1):60-2. PubMed ID: 18187830
    [No Abstract]   [Full Text] [Related]  

  • 24. [Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus].
    Ruiz de Casas A; García-Bravo B; Camacho F
    Actas Dermosifiliogr; 2005 Mar; 96(2):122-3. PubMed ID: 16476350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
    Shen Y; Pielop J; Hsu S
    Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158
    [No Abstract]   [Full Text] [Related]  

  • 26. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
    Jensen DM; Marcellin P
    Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):899-904. PubMed ID: 16093865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
    Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 36. Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
    Fredlund P; Hillson J; Gray T; Shemanski L; Dimitrova D; Srinivasan S
    J Interferon Cytokine Res; 2015 Nov; 35(11):841-3. PubMed ID: 26376344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
    Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acute pancreatitis in a hepatitis C positive patient following treatment with peginterferon alfa-2b and ribavirin].
    Kok KF; de Vries RA
    Ned Tijdschr Geneeskd; 2006 Mar; 150(12):681-3. PubMed ID: 16613253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.